Journal article
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours
Abstract
Background:SB939 is an orally available, competitive histone deacetylase (HDAC) inhibitor selective for class I, II and IV histone deacetylases. Preclinical evaluation of SB939 revealed a profile suggesting improved efficacy compared to other HDAC inhibitors. This phase I study was carried out to determine the safety, dose-limiting toxicity, recommended phase II dose (RPTD), as well as pharmacokinetic (PK) and pharmacodynamic (PD) profiles of …
Authors
Razak ARA; Hotte SJ; Siu LL; Chen EX; Hirte HW; Powers J; Walsh W; Stayner L-A; Laughlin A; Novotny-Diermayr V
Journal
British Journal of Cancer, Vol. 104, No. 5, pp. 756–762
Publisher
Springer Nature
Publication Date
March 2011
DOI
10.1038/bjc.2011.13
ISSN
0007-0920